Recent studies exploring injection techniques in intertumoral drug delivery, drug formulation, and tumor stroma on the efficacy of the STING agonist on tumor cells have found that STING agonists are significantly more effective in soft tumors such as melanoma than firm tumors such as colorectal cancer [43]. The gene discussed is STING1; the disease is colorectal cancer.